

P-04-460 Lives not Airports – Announcement by the Minister for Health and Social Services

Recommendations on Pegvisomant (Somavert®)

The Minister for Health and Social Services has agreed to endorse the All Wales Medicines Strategy Group recommendation.

Date of decision:

19 December 2013

Statement of information:

The aim of All Wales Medicines Strategy Group (AWMSG) is to provide advice in an effective, efficient and transparent manner to the Welsh Ministers on strategic medicines management and prescribing. This enables the Welsh Ministers to provide guidance on a standard pattern of approach to prescribing issues across Wales whilst permitting local application but reducing duplication of effort.

The Minister for Health and Social Services is being asked to endorse the following AWMSG recommendation made at the 16 October 2013 meeting:

- Pegvisomant (Somavert®) is not recommended for use within NHS Wales for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-1 concentrations or was not tolerated.

Links:

Further information can be accessed on the AWMSG's website: www.wales.nhs.uk/awmsg/ (external site)